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Plasmablastic transformation of a pre-existing 
plasmacytoma: a possible role for reactivation of
Epstein Barr virus infection
The distinction between plasmablastic lymphoma (PBL)
and plasmacytoma may be confidently made on the basis
of histopathological and clinical features. However, some
cases can be challenging owing to a morphological overlap.
The main significant differences include genetic aberrations
[i.e. t(11;14); t(4;14), hyperdiploidy], and in particular the
presence of Epstein-Barr virus (EBV)-encoded RNA (EBER),
which is detectable in 75-100% of all PBL cases, in contrast
to plasmacytoma (10% of cases).1 The exact role of EBV in
the pathogenesis of PBL is still poorly understood.2
Although it has been suggested that PBL may occur as a
high-grade transformation from a pre-existing plasmacy-
toma following EBV infection, this concept has not been
well established and definitive proof is lacking.3,4
In December 2011, a 74-year old man presented for a
right maxillary sinus solitary mass, infiltrating the oral cav-
ity. Histological examination of the bioptic specimen
showed a uniform proliferation of plasma cells with abun-
dant cytoplasm, round eccentrically located nuclei and
clock-face chromatin without nucleoli (Figure 1A).
Neoplastic cells expressed CD38, CD138, CD79a, MUM-1;
they were restricted for immunoglobulin heavy chain G
(IgG) and light chain lambda (Igλ). CD20 and PAX-5 were
negative. The proliferative index (Ki-67) was approximate-
ly 10%. A complete workup with computer tomography
(CT) scan and bone marrow biopsy excluded other sites of
involvement; therefore, the final diagnosis was extra-
osseous plasmacytoma. The patient was treated with one
cycle of chemotherapy with: bortezomib 1.3 mg/m2 Days
1, 4, 8, 11; melphalan 9 mg/m2 Day 1-4; and prednisone 50
mg Days 1, 4, 8, 11 (VMP scheme), obtaining a 90% reduc-
tion of the mass. Subsequently, a 50 Gy of involved field
radiotherapy treatment led to a complete remission, which
was confirmed at CT/positron emission tomography. Ten
months later the patient relapsed. The histological evalua-
tion of the surgical specimen confirmed the previous diag-
nosis; however, an increase in the proliferative index was
detected (Ki-67 approximately 40%). The patient was
treated again with bortezomib associated with cyclophos-
phamide 500 mg Days 1, 8, and dexamethasone 20 mg
Days 1, 4, 8, 11, achieving only a minimal response.
Therefore, he was switched to a third-line therapy with
lenalidomide 25 mg Days 1 and 21, cyclophosphamide 750
mg Days 1 and 8, and dexamethasone 20 mg every week
(RCD scheme), obtaining an excellent but short response
with a rapid growth of the mass in May 2013. The patient
underwent surgical excision of the neoplastic lesion; labo-
ratory tests showed hemoglobin 13.9 g/dL, white blood cell
count 8.32 x 109/L, platelets 408 x 109/L. The histological
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Figure 1. Morphological features of the samples. (A) A uniform population of plasma cells with abundant cytoplasm, round eccentrally
located nuclei  and clock-face chromatin without nucleoli is observed. (B) A small percentage of tumor cells are EBER-positive. 
(C) Neoplastic population is characterized by monoclonal IGHV rearrangement. (D) Histological specimen shows a diffuse and cohesive
proliferation of round- to oval-shaped large cells with scant cytoplasm, and prominent nucleoli. (E) EBER positivity is observed in 90% of
the neoplastic cells. (F) The same IGHV rearrangement of the plasmacytoma samples is shown. (G) EBNA1, and (H) Ea-D and (I) Ea-R
expression in blastic cells of the plasmablastic lymphoma sample is present. [A, D: Haematoxylin and Eosin; B, E: EBER in situ hybridiza-
tion; G: EBNA1 stain; H: Ea-D stain; I: Ea-R stain. A-B, D-E, G-I: original magnification: 20x].
examination of the specimen showed a diffuse and cohe-
sive monomorphic proliferation of round- to oval-shaped
large cells with scant cytoplasm, and prominent nucleoli
(Figure 1D). Neoplastic cells were CD38, CD138 and
MUM-1 positive, IgG/λ restricted, and CD20, CD79a, and
PAX5 negative. The proliferative index (Ki-67) was approx-
imately 95%. EBER was present in 90% of the neoplastic
cells (Figure 1E). All of the neoplastic cells expressed the
MYC protein. FISH analysis using dual-color break-apart
probes did not identify any of the known translocations
involving the MYC gene. To evaluate whether we were
dealing with the transformation of the pre-exisisting plas-
macytoma, CD56 and cyclin D1 positivity was checked in
all the specimens.5 Both plasmacytomas and plasmablastic
samples expressed CD56, whereas no cyclin D1 staining
was identified. In addition, IGH-VDJ rearrangement was
performed in all the specimens according to BIOMED-2
protocol by using framework regions 2 (FR2VH) and JH
regions primers (VHFR2-JH).6 A productive IGHV
rearrangement (VH3-23, DH3-22, JH4*02) with 93.27%
identity of germ-line sequence was detected, thus confirm-
ing the clonal relationship of all the samples (Figure 1C and
F). The final diagnosis was plasmablastic transformation of
pre-existing plasmacytoma of the oral cavity. The patient
was treated with liposomial doxorubicin 50 mg/m2 Day 1
and cytosine arabinoside 2 g Days 1-2, obtaining a minimal
response. Thus, bendamustine 90 mg/m2 Days 1-2 for two
cycles was administrated but with no response.
Since EBV reactivation has been observed following
bortezomib therapy,7 it was hypothesized that EBV was the
trigger responsible for the transformation of plasmacytoma
in PBL, determining the multiple rapid relapses of the dis-
ease. Therefore, we checked EBV also in the plasmacytoma
samples. Interestingly, in these cases, only a small percent-
age of tumor cells with blastic appearance were EBER-pos-
itive, increasing from the first (10%) to the second (30%)
biopsy (Figure 1B). In addition, the first sample was nega-
tive for MYC, whereas in the second specimen 30% of the
neoplastic cells expressed the protein. Since the oncogenic
role of EBV is controversial, and the type of viral program
expressed by plasmablastic lymphoma is still a matter of
debate, a complete genetic assessment of the virus latency
and lytic genes by RT-qPCR and immunohistochemistry
was performed. The expression of EBNA1 and the negativ-
ity for LMP-1 and EBNA-2 in all the three biopsies suggest-
ed a type I latency (Figure 1G). In the third biopsy, we
detected expression of some genes/proteins involved in the
lytic cycle (BZLF1, BMRF1, BHRF1 coding for the Zebra,
Ea-D and Ea-R/p17 proteins, respectively) (Figure 1H-I).
The fact that we did not find BLLF1- gp350/220 expression
suggests an abortive lytic cycle in neoplastic cells.8 It is
known that the reactivation of lytic cycle may play a role in
EBV-driven lymphomagenesis by increasing the total num-
ber of latently infected cells.9 In addition, viral lytic genes,
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Figure 2. Head computed tomog-
raphy findings. A reduction of the
mass is observed between the
first (A) and the second (B) head
computed tomography (arrows). 
Figure 3. microRNAs relative  expression level. In
plasmablastic sample (PBL) a downregulation of hsa-
miR34b, hsa-miR155, hsa-let7a, hsa-miR29a and 
-29b is detected, in comparison to normal  lymph
node and to MYC translocation-positive (MYC t+)
Burkitt lymphoma (BL) samples.
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or cellular genes induced by viral lytic proteins could poten-
tially encode paracrine factors that promote tumor
growth.10 A number of physiological stimuli and chemical
agents may favor the lytic form of EBV infection, including
B-cell receptor stimulation, transforming growth factor-β,
hypoxia and DNA damage.11 Since no response has been
obtained by conventional therapy, and considering the high
viral load in the blood (264,000 DNA copies/mL), the same
therapy of post-transplant lymphoproliferative disorders
(PTLD) was performed. Accordingly, rituximab 375 mg/m2
weekly for three doses and acyclovir were added to a con-
tinuous lenalidomide treatment Days 1-28 per month at 15
mg/day with the aim of: i) increasing potential response; ii)
reducing the reservoir of latently infected cells; and iii)
decreasing viral burden. Emerging data have suggested that
rituximab may have therapeutic value also in patients with
tumors which do not express CD20 by eliminating reactive
B lymphocytes in the microenvironment that may support
the growth and survival of neoplastic cells.12,13 Depleting
reactive B cells may also enhance the anti-lymphoma
immune response.  As far as the rationale of using acyclovir
is concerned, recent data on nasopharyngeal carcinoma
and glioblastoma indicate that antiviral drugs may improve
outcomes in viral-associated tumors by inhibiting lytic
replication.14 
In our case, the therapy induced a marked reduction of
the mass, in parallel to a decrease in viral load (12,250 DNA
copies/mL) (Figure 2A and B). At the last follow up (eleven
months later) the patient was in complete remission.          
In conclusion, the importance of our case consists in
drawing attention to two main issues. First of all, it should
be underlined that MYC protein expression can occur also
in the absence of MYC translocation and may probably be
due to alternative mechanisms, likely involving microRNA
(miRNA) dysregulation. In our case, a downregulation of
some miRNAs known to regulate MYC expression (i.e.
hsa-miR34b, hsa-miR155, hsa-let7a, hsa-miR29a and -29b)
has been detected, in comparison to normal lymph node
and to MYC translocation-positive Burkitt lymphoma cases
(Figure 3).15 This finding may explain the upregulation of
MYC in the absence of the MYC translocation. On the
other hand, the pathologist should consider the possibility
of staining all plasmacytomas and probably all plasma cell
myelomas for EBV in order to identify those patients at
higher risk of transformation to PBL, which require a totally
different and more aggressive therapeutic protocol and a
closer follow up. In those patients in whom plasmacytoma
de-differentiate to PBL, the therapeutic regimens used in
PTLD to reduce the reservoir of latently infected cells and
to inhibit lytic replication should be taken into account to
improve the prognosis. Enhanced understanding of the
multiple mechanisms regulating EBV reactivation will,
hopefully, lead to the development of minimally toxic,
highly specific therapies. The use of routine chemotherapy
in combination with acyclovir appears to be a promising
approach for treating patients with EBV-positive tumors. 
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